by admin | 3rd May 2023 | News
London and New York, NY, May 3, 2023 – OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this... by admin | 24th March 2023 | News
London and New York, NY, 24 March, 2023 – OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company“), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED“) to address the significant unmet... by admin | 16th March 2023 | News
London and New York, NY, March 16, 2023 – OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar... by admin | 15th March 2023 | News
OKYO Pharma Limited (“OKYO” or the “Company”) Grant of options –PDMR dealing London, March 15, 2023 – OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company“), an ophthalmology-focused bio-pharmaceutical company which is... by admin | 14th March 2023 | News
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY...